Orviva

Learn · Pharmacogenomics

HLA-C*06:02

Psoriasis Susceptibility.

Curated from CPIC / guidelines

What is HLA-C*06:02?

HLA-C*06:02 is a variant of a human leukocyte antigen (HLA) gene, the system the immune system uses to present fragments of proteins — including drugs bound to proteins — to T cells. Particular HLA alleles bind particular drugs, which is why carrying one can turn an ordinarily safe medicine into a severe immune reaction, and why some alleles track autoimmune conditions.

How common is HLA-C*06:02?

European10.0%
East Asian5.0%
African8.0%
Global8.0%

Conditions linked to HLA-C*06:02

Psoriasis Susceptibility high risk
HLA-C*06:02 is the strongest genetic risk factor for psoriasis (especially type I/early-onset psoriasis). Carriers have ~10-fold increased risk. If skin symptoms develop (red, scaly patches), early dermatological evaluation can improve management.
Evidence: GWAS OR ~10-12; PSORS1 locus · Source: International Psoriasis Genetics Consortium; Nature Genetics 2009 · HLA-C*06:02 frequency: ~10% in Europeans, ~5% in East Asians. Present in ~60% of psoriasis patients.

How is HLA-C*06:02 inferred from a consumer DNA file?

Consumer chips do not sequence HLA genes. HLA-C*06:02 is inferred from the tag SNP rs10484554 (risk allele T), which travels with the HLA allele on the same stretch of chromosome. How reliably it does so (r²) differs by ancestry:

European0.9
East Asian0.85
African0.75
Global0.85

A tag-SNP call is a probability, not a laboratory HLA type. A positive result that would change a prescription should be confirmed by clinical HLA typing.

Genetic associations describe risk across populations, not a diagnosis for any one person. Most variants shift risk modestly and act alongside lifestyle, environment and other genes. Consumer DNA chips do not read every position and can be wrong at any single one. For general education only; talk to a clinician or genetic counsellor before acting on anything here, and never change a prescribed medicine without your prescriber.